BR0113312A - Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes - Google Patents

Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Info

Publication number
BR0113312A
BR0113312A BR0113312-8A BR0113312A BR0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A
Authority
BR
Brazil
Prior art keywords
compounds
type
composition
tetrazole
diabetes
Prior art date
Application number
BR0113312-8A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113312A publication Critical patent/BR0113312A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0113312-8A 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes BR0113312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
PCT/EP2001/009207 WO2002014312A1 (en) 2000-08-15 2001-08-09 Tetrazolyl-phenyl acetamide glucokinase activators

Publications (1)

Publication Number Publication Date
BR0113312A true BR0113312A (pt) 2003-07-01

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113312-8A BR0113312A (pt) 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Country Status (20)

Country Link
US (3) US6369232B1 (enExample)
EP (1) EP1311504B1 (enExample)
JP (1) JP3961948B2 (enExample)
KR (1) KR100518061B1 (enExample)
CN (1) CN1209362C (enExample)
AR (1) AR031718A1 (enExample)
AT (1) ATE297921T1 (enExample)
AU (2) AU8399801A (enExample)
BR (1) BR0113312A (enExample)
CA (1) CA2419416C (enExample)
DE (1) DE60111540T2 (enExample)
DK (1) DK1311504T3 (enExample)
ES (1) ES2243541T3 (enExample)
MX (1) MXPA03001275A (enExample)
PA (1) PA8525201A1 (enExample)
PE (1) PE20020386A1 (enExample)
PT (1) PT1311504E (enExample)
UY (1) UY26885A1 (enExample)
WO (1) WO2002014312A1 (enExample)
ZA (1) ZA200300904B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
PT1735322E (pt) * 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
RU2420525C2 (ru) * 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
ES2381864T3 (es) * 2005-12-15 2012-06-01 Nihon Nohyaku Co., Ltd. Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008084872A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
US8034819B2 (en) * 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
ES2446932T3 (es) * 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
AU2009205070A1 (en) 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
IL131130A0 (en) * 1997-01-28 2001-01-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
HK1046139B (zh) * 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂

Also Published As

Publication number Publication date
EP1311504B1 (en) 2005-06-15
CN1466584A (zh) 2004-01-07
CA2419416C (en) 2009-10-13
DE60111540T2 (de) 2006-03-16
KR20030022408A (ko) 2003-03-15
PT1311504E (pt) 2005-10-31
US6388088B1 (en) 2002-05-14
US20020065275A1 (en) 2002-05-30
US6441180B1 (en) 2002-08-27
WO2002014312A1 (en) 2002-02-21
EP1311504A1 (en) 2003-05-21
ZA200300904B (en) 2004-04-30
DE60111540D1 (de) 2005-07-21
PE20020386A1 (es) 2002-05-13
US20020035267A1 (en) 2002-03-21
ATE297921T1 (de) 2005-07-15
AU8399801A (en) 2002-02-25
CA2419416A1 (en) 2002-02-21
US20020035266A1 (en) 2002-03-21
PA8525201A1 (es) 2002-07-30
JP2004506632A (ja) 2004-03-04
ES2243541T3 (es) 2005-12-01
JP3961948B2 (ja) 2007-08-22
US6369232B1 (en) 2002-04-09
AR031718A1 (es) 2003-10-01
DK1311504T3 (da) 2005-10-17
MXPA03001275A (es) 2003-06-30
KR100518061B1 (ko) 2005-09-28
CN1209362C (zh) 2005-07-06
UY26885A1 (es) 2002-02-28
AU2001283998B2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CA2419416A1 (en) Tetrazolyl-phenyl acetamide glucokinase activators
BR0114708A (pt) Compostos, composições farmacêuticas que compreendem os mesmos, utilização dos compostos, processo de tratamento de distúrbios e de obesidade, e processos para a preparação dos compostos e de uma composição
BR0208126A (pt) Conjugados de ingrediente ativo de has
EP1423111A4 (en) FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
MXPA03006918A (es) Compuestos heterociclicos fusionados.
BR0110704A (pt) Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
AR041467A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
BR0115999A (pt) Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0309964A (pt) Derivados anticonvulsivos de sulfamoto substituìdo
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
NZ705710A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
BR0112856A (pt) Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
BRPI0506676A (pt) piridazinona uréias como antagonistas de integrinas alfa4
ATE457971T1 (de) Derivate von 4-hydroxybutansäure und deren höheren homologen als liganden von g- hydroxybutyrat- (gbh-)rezeptoren, pharmazeutische zusammensetzungen, die diese enthalten, und pharmazeutische anwendungen
BR0208688A (pt) Lipìdeo diminuindo bifenil carboxamidas
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
DE60221348D1 (de) Substituierte chinoline zur behandlung von durch protozoen und retroviren verursachten co-infektionen
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
WO2006126939A8 (en) Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
Liu et al. Overcoming radical stability order via DABCO-triggered desulfurization: Visible-light-promoted 1, 2, 4-trifunctionalization of butenyl benzothiazole sulfone with thiosulfonate

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.